Board of Directors

Dr. Anderson is Kraft Family Professor of Medicine at Harvard Medical School as well as Director of the Lebow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center at the Dana-Farber Cancer Institute. He has over four decades of experience researching multiple myeloma  in both laboratory and clinical settings. Dr. Anderson is the recipient of several awards including the International Myeloma Foundation Robert A. Kyle Lifetime Achievement Award; the American Association for Cancer Research Joseph H. Burchenal Award, the American Society of Hematology William Dameshek Prize, and the American Society of Clinical Oncology David A. Karnofsky Award. He is a member of the Institute of Medicine of the National Academy of Sciences, and has served as President of the International Myeloma Society and the American Society of Hematology.

Mr. Baum brings twenty years of experience in advising Executive leadership teams for both well-established Fortune 50 companies and emerging ventures, across a spectrum of industries including life sciences, education, travel, real estate and technology.

In his concurrent roles as Managing Director of Acquis Consulting Group and Managing Director / Co-Founder of its affiliate, Solidea Capital, Mr. Baum leverages his extensive management and operational consulting expertise to guide companies in areas such as business and corporate strategy, market positioning, growth and scale strategies, trajectory management, partnering frameworks, risk evaluation, and more. He also serves in several advisory and Board of Director roles for public and private companies such as KushCo Holdings, Big Rentz Tenant Tracker, Data Exchange, supporting the full lifecycle of needs from idea conception through expansion and growth strategies.  Mr. Baum is also actively involved in the venture capital arena as an angel investor and participant in several investment-focused groups, such as the Charlotte Angel Fund.  Mr. Baum received a Bachelor of Business Administration from Emory University where he graduated valedictorian from the Goizueta Business School. He was awarded the Goizueta Business School Organizational Management Highest Award for Excellence and was inducted into Beta Gamma Sigma, the highest national business honor society.

Mr. Dodo has 35+ years experience focused on the USA and Latin America, he has built strong relationships with regulators, media, government, corporate, distributors, and industry leaders. Most recently, Moses Dodo served as the Chairman, Bupa Global LATAM (BGLA) spearheading corporate development and inorganic growth. Prior to the Chairman role, Moses was General Manager of BGLA. He was also the CEO and Chairman of Amedex Bermuda, a Life Insurance company. Moses served as a Board member of HtH Geoblue, a partnership with the Blue Cross Blue Shield offering IPMI in the USA.

Moses joined Bupa following 6 successful years at Haitong Bank (formerly Espirito Santo Investment Bank) where he served as the Senior Managing Director and Board member responsible for all North American operations, including the offices in New York and Mexico City.

Previously, Moses also served as General Manager and Divisional Board member for WestLB Bank in New York, from 2001 until 2007, after building his banking career for 17 years in WestLB do Brazil.

Mr. Dodo holds a bachelor’s degree in Business Administration & Finance from Fundação Armando Alvares Penteado, Sao Paulo, Brazil. He is a dual citizen of Brazil and United States and speaks English, Spanish, Portuguese, French, and Italian. He and his family reside in south Florida, where he is active in the community.

Dr. Mohamad Hussein, MD, currently severs as a Professor of Medicine and Oncology at the University of South Florida College of Medicine.

With over 30 years of combined academia and pharmaceutical experience in hematologic malignancies, cell therapy, hematology and oncology, Dr. Hussein is considered a global leader. He has been published over 100 times, and served as the Editor in Chief (International Journal of Surgical Oncology), a review member (Lancet, Medical Science Monitor, International Medical Journal for Experimental and Clinical Research, CME American Society of Clinical Oncology, and Panasonic Laptop Development) and consultant to the scientific journal community. His vast involvement with clinical trials and funded research spans across the nation.

Dr. Hussein served on 6 committees at H Lee Moffitt Cancer and Research Center between 2006-2008, as well as 5 committees at Cleveland Clinic (1991-2006), and 22 additional external committees and advisory boards throughout his career. As a Medical Affairs leader, Dr. Hussein left a significant footprint from his tenure at Celgene. His accomplishments include building a robust Medical Affairs division, creating a Global Hematology physician group, driving the pipeline strategy for multiple myeloma, and life cycle management.

An industry executive with a 37-year career in biotechnology and a proven track record of managing and developing business, executing strategic alliances, and building commercial and R&D capabilities.

He is the former President of Global Primary Care and President of Europe at Pfizer Inc with 16 years’ experience, and the former CEO of Asterias Biotherapeutics and Optimer Pharmaceuticals.

He holds an MBA degree from Wharton School of Business and an engineering degree from the National University of Mexico.

Mr. Nitin Kaushal, CPA, CA has over 30 years of financial and investment experience with an expertise focused on
the life sciences industry.

Mr. Kaushal currently sits on the boards of a number of private and publicly listed companies. Mr. Kaushal has held senior roles in the investment banking, venture capital and consulting industry with a focus on the healthcare industry. He has performed a number of mergers/acquisitions, strategic advisory, and licensing assignments for a number of the global pharma companies. Mr. Kaushal is a regular speaker at biotechnology conferences including BIO and Biofinance.

Dr. Fotios Plakogiannis, BSc, MS, Ph.D. is the managing Director at TRPL, based in Long Island City, New York.  Dr. Plakogiannis served as a Professor at the Arnold & Marie Schwartz College of Pharmacy, LIU for over 45 years, where 25 of those years he was the Director of the Division of Pharmaceutical Sciences.

He was instrumental in establishing their Scientific Graduate Division for MS & Ph.D. program. He has mentored more than 200 MS and Ph.D. degrees, served as chair of the Academy of Pharmaceutical Sciences Basic Pharmaceutics Section, and has presented his work throughout the USA and Europe.  He was the Founder, Chairman of the Board (for one year) and Board member of Aequus Pharmaceuticals Inc. from January 2014 until July 2018. Dr. Plakogiannis has been a visiting Professor in several universities, including but not limited to Kentucky University and the University of Arizona.

In addition, he has acted as a consultant for the Pharmaceutical Industry and has served as an expert witness in several cases.  Dr. Plakogiannis has authored three books and more than 100 research papers with the majority in the area focused on Transdermal Delivery. He was the recipient of the TASA Award for Lifetime Achievement at LIU, Founders Award, etc., among other prestigious awards.

Dr. Roy Waldron, Ph.D., J.D, served as the Senior Vice President‚ Associate General Counsel and Chief Intellectual
Property Counsel at Pfizer.

There, he led global teams of Pfizer attorneys and professionals in procuring patents‚ and worked closely with R&D‚ Business Development and Pfizer Business Units to develop and strengthen intellectual property strategies for development and acquisition targets. Dr. Waldron has been published numerous times, and often serves as a panelist and keynote speaker at events. He has participated in many industry related committees, including International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)‚ Pharmaceutical Research and Manufactures of America (PhRMA)‚ INTERPAT, Intellectual Property Owners Association (IPO), Hoover IP 2 , Association of Corporate Counsel (ACPC) and Gibbons Institute of Law Science and Technology. Dr.

Waldron holds a JD from New York University Law School‚ a PhD from Yale and a BA from Dartmouth College.